Legal & General Group Plc Purchases 18,268 Shares of Solventum Corporation $SOLV

Legal & General Group Plc increased its stake in shares of Solventum Corporation (NYSE:SOLV) by 3.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 550,766 shares of the company’s stock after acquiring an additional 18,268 shares during the period. Legal & General Group Plc’s holdings in Solventum were worth $43,643,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of SOLV. Assetmark Inc. raised its stake in shares of Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after purchasing an additional 128 shares in the last quarter. Hilltop National Bank raised its stake in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares in the last quarter. Allworth Financial LP raised its stake in shares of Solventum by 2.8% during the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares in the last quarter. CIBC Private Wealth Group LLC raised its stake in shares of Solventum by 0.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after purchasing an additional 134 shares in the last quarter. Finally, BOKF NA raised its stake in shares of Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after purchasing an additional 141 shares in the last quarter.

Solventum Stock Down 1.1%

SOLV stock opened at $75.13 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The firm has a market capitalization of $13.01 billion, a PE ratio of 9.21, a PEG ratio of 1.16 and a beta of 0.59. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The business’s 50 day simple moving average is $69.57 and its 200 day simple moving average is $75.04.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the prior year, the firm posted $1.34 EPS. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Insider Buying and Selling

In other news, Director Amy Mcbride Wendell acquired 1,475 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were purchased at an average cost of $68.03 per share, with a total value of $100,344.25. Following the acquisition, the director directly owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.24% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SOLV. Rothschild & Co Redburn began coverage on Solventum in a research note on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective on the stock. BTIG Research reiterated a “buy” rating and set a $89.00 price objective on shares of Solventum in a research note on Wednesday, May 6th. Piper Sandler dropped their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Wells Fargo & Company dropped their price objective on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Finally, UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Thursday, May 14th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Solventum currently has a consensus rating of “Moderate Buy” and an average price target of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.